Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. (2019)

Peer-Reviewed Study · Andrea Emanuele Guerini; Luca Triggiani; Marta Maddalo et al. · August 31, 2019

Andrea Emanuele Guerini et al., 2019-08-31: Extensive review of mebendazole as a repurposing candidate in oncology, organised around resistant cells and cancer stem cells. Lists the mechanisms the preclinical literature claims.

Several in vitro studies suggest that MBZ inhibits a wide range of factors involved in tumor progression such as tubulin polymerization, angiogenesis, pro-survival pathways, matrix metalloproteinases, and multi-drug resistance protein transporters.

Andrea Emanuele Guerini et al., 2019-08-31: Extensive review of mebendazole as a repurposing candidate in oncology, organised around resistant cells and cancer stem cells. Lists the mechanisms the preclinical literature claims. Study type: narrative review. N: not applicable. Country: Italy (Brescia University). Dose: not applicable (review). Funder: not stated in the record. Declared conflicts: 'The authors declare no conflict of interest.' Product: none. Comparator: not applicable. Also filed as MBC-34 (claims C1, C6). Study type: review.